Oncology CME Review Course

Prostate Cancer Management:  A Date Analysis Judd W. Moul, M.D., John E. Sylvester, M.D. and Richard G. Stock, M.D.  Distinguish between watchful waiting and active surveillance (AS) in prostate cancer patients.  Employ the AS approach in patients with prostate cancer.  Analyze the risk for radiation-induced secondary malignancy after prostate irradiation.  Discuss the results of studies comparing the relative risks for secondary malignancy from external beam radia tion therapy with other modalities.   Recognize the pathologic features that predict durable response from radiation after prostatectomy.

New Frontiers in Prostate Cancer Management  David I. Quinn, M.D., P.h.D., Abraham Morgentaler, M.D. and E. David Crawford, M.D.  State the advantages and disadvantages of docetaxel as chemotherapy for prostate cancer.  Discuss ways of managing skeletal complications of prostate cancer chemotherapy.  Describe the general strategy underlying many new chemotherapeutic agents for prostate cancer.  Explain why vascular endothelial growth factor (VEGF) is the target of so many new drugs.  Compare the advantages and disadvantages of injections and implants for hormone therapy of prostate cancer. 

Observations on Cancer Treatment and Rehabilitation  Carol R. Bradford, M.D., Paul M. Harari, M.D. and Tessa Goldsmith, M.A. C.C.C.–S.L.P.  Describe the organ-preserving options available to a patient facing possible total laryngectomy.  Determine when total laryngectomy is indicated.  Discuss the latest advances in treatment precision with radiation therapy.  Review the outcomes of radiation therapy in early and advanced glottic cancer. Utilize methods for improving postchemoradiation dysphagia.

Contemporary Issues in Breast Cancer  Leo B. Twiggs, M.D., Deborah J. Rhodes, M.D. and Katherine S. Hunt, M.S.  Identify women at increased risk for breast cancer.  Determine the appropriate surveillance and risk-reducing strategies for breast cancer.  Provide appropriate follow-up care for women with a history of breast cancer.  Identify and treat complications of therapy for breast cancer.  Educate patients about direct-to-consumer marketing of genetic testing.

Breast Cancer Surgery  Leigh A. Neumayer, M.D., M.S., Patrick J. O'Neill, M.D. and Anne Marie Wallace, M.D.  Compare and contrast lumpectomy and mastectomy, with regard to breast cancer recurrence, morbidity, and mortality.  Discuss the roles of chemotherapy and radiation therapy in breast cancer management and their impact on the choice and timing of surgery.  Educate patients about options for breast reconstruction after mastectomy or lumpectomy.  Design a treatment plan for pregnant women with breast cancer, taking into consideration trimester of pregnancy and stage of tumor.  Discuss the contraindications associated with pregnancy and lactation, as they apply to breast cancer screening and management.

Cancer in the Family/Pancreatic Cancer  Lori Ballinger, M.S.and Howard A. Reber, M.D.  Recognize the risk factors for inherited predisposition to cancer and describe the major mutations causing breast, colon, and other cancers.  Choose the appropriate therapeutic strategy for patients with BRCA mutations, Cowden disease, Li-Fraumeni syndrome, and familial adenomatous polyposis (FAP).  Describe the role and benefits of genetic counseling in the management of patients with suspected inherited predisposition to cancer.  Summarize the contributions of recent advances in molecular genetics, diagnosis and staging, surgical procedures, and adjuvant therapies in improving mortality of patients with pancreatic cancer.  Employ surgical modifications that reduce blood loss and improve operative mortality during resection of pancreatic cancers.

Technology and Renal Cancer Managment  Jeffrey A. Cadeddu, M.D., Bradley C. Leibovich, M.D. and J. Kellogg Parsons, M.D., M.H.S.  Identify patients with RCC who are candidates for active surveillance.  Describe the available systemic therapies for patients with metastatic RCC.  Discuss the role of surgery in managing metastatic RCC.  Design a multimodal management plan for patients with metastatic RCC.  Compare and contrast cryotherapy and radiofrequency ablation in the management of small RCCs.

Prostate Cancer Management:  Trends in Practice  Leonard G. Gomella, M.D., J. Kellogg Parsons, M.D., M.H.S. and Alan Pollack, M.D., P.h.D.  Recognize the risk factors for PCa, including family history, age, and race.  Discuss the advantages and disadvantages of screening for PCa.  Recommend a high-vegetable diet to decrease risk for PCa.  List food products found to be beneficial in decreasing risk for PCa.  Cite important studies looking at androgen deprivation plus radiation therapy as treatment for PCa.

Renal Cancer:  Current Data and Concepts  Christopher J. Kane, M.D. and Brian I. Rini, M.D.  Cite recent data documenting an increase over time of the percentage of newly diagnosed RCC patients who present with stage I disease.  State the overall therapeutic goal in the management of advanced RCC.  Discuss data on targeted therapy in RCC with regard to objective response rates (ORR), progression-free survival (PFS) and overall survival (OS).  Explain the rationale for considering initial observation of patients with advanced RCC and identify those who are appropriate candidates for this approach.  Describe the evidence supporting the use of cytoreductive nephrectomy before systemic therapy in advanced RCC and explain the advantages of laparoscopic vs open procedures.   

Thyroid Cancer:  Focusing Care  Stephanie L. Lee, M.D., P.h.D., Erik K. Alexander, M.D. and Jeremy L. Freeman, M.D.  List factors not in the TNM system that increase the risk for death in patients with thyroid cancer.  State the American Thyroid Association (ATA) guidelines for management of thyroid lesions classified as indeterminate on fine needle aspiration (FNA) biopsy and for surgery of differentiated thyroid carcinoma.  Discuss the use of FNA for evaluation of thyroid nodules.  Describe a technique for performance of FNA that is derived from a consensus of experts in the field.  Review the clinical behavior of Hürthle cell tumors and evaluate a proposed classification scheme for these tumors that includes the ret/PTC oncogene.

Possible Additional Course Available

If you have taken the current course listed here or if you need additional Oncology credits, please call 800-446-5599 and ask about new courses in stock that are not listed on the website.